← Back to Search

Antifungal

UHE-103 Cream for Athlete's Foot

Phase 1
Waitlist Available
Research Sponsored by Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 16
Awards & highlights

Study Summary

This trial is testing a new cream for treating skin fungal infections. The main goals are to see if it is safe and tolerated by people, and how it is absorbed into the body.

Eligible Conditions
  • Jock Itch
  • Athlete's Foot

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC (0-12 hours)
Adverse Events (AEs)
Local Skin Reactions (LSRs)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: UHE-103 CreamExperimental Treatment1 Intervention
Subjects will apply at least a total of 4 grams* of the test article, covering both feet twice daily for 2 weeks
Group II: Naftin (naftifine hydrochloride) Cream, 2%Active Control1 Intervention
Subjects will apply at least a total of 5 grams* of the test article, covering the interdigital areas of both feet and to the groin once daily for 2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UHE-103 Cream
2022
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Therapeutics, Inc.Lead Sponsor
30 Previous Clinical Trials
3,870 Total Patients Enrolled
Tony AndrasfayStudy DirectorTherapeutics Inc. (CRO)
6 Previous Clinical Trials
520 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
2022. "Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05363449.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top